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Nephropathy is one of the major complications of diabetes often leading to chronic kidney disease (CKD).
Inflammation and oxidative stress are associated with pathogenesis of diabetic nephropathy (DN) and found to be
regulated by nuclear receptors such as vitamin D receptors (VDR). Vitamin D and its analogues have been effectively
used in patients with CKD. The review attempts to summarize the available evidence on the role of vitamin D in DN.
Electronic databases (MEDLINE, EMBASE, and Cochrane Library) were searched for studies assessing the role of vitamin
D or its analogues on kidney function in type 2 diabetic patients. Studies evaluating kidney functions (urinary albumin/
protein creatinine ratio, albuminuria and eGFR) were included and quality and risk of bias assessment performed.
Additionally effect on 25 (OH) vitamin D, calcium and HbA1c were evaluated. The mean or its % change along with
their standard deviation (SD) was used for reporting our results. RevMan (V5.2) was used for data analysis. Six studies
included in this review evaluated the role of cholecalciferol, calcitriol and paricalcitol in patients with DN. Study designs
differed (three randomized, one non-randomized and two uncontrolled trials) with varying degree of quality and risk of
biases. Vitamin D analogues showed significant improvement in kidney function in two randomized studies. None of
the studies reported significant incidences of hypercalcemia. Vitamin D analogues show significant improvement of
kidney function in DN. Randomized controlled trials with longer duration, comparing the efficacy of vitamin D and its
analogues are needed.
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Diabetic nephropathy (DN) is a major microvascular com-
plication of diabetes mellitus implicated in nearly 44 % of
end stage renal disease (ESRD) patients that requires
hemodialysis [1]. Type 2 diabetes has assumed a global
pandemic proportion with estimates of approximately 382
million people with diabetes in 2013 and an expected rise
to 592 million by 2035 with an anticipated increase in its
complications such as nephropathy [2].
The pathogenesis of DN is multifactorial with contribu-
tion from several genetic and environmental factors.
Diabetes induces various metabolic, biochemical and
hemodynamic changes in kidneys. Major pathways leading
to DN include: intracellular activation of polyol pathway
and protein kinase C, advanced glycation end products
(AGEs) and oxidative stress by reactive oxygen species,* Correspondence: c.mrunalini@gmail.com
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to shear stress and mechanical stretch [3]. Hyperglycemia
stimulates the production of Angiotensin II (Ang II),
which exerts hemodynamic, inflammatory and profibro-
genic effects on kidney cells [4]. Transcription factor like
nuclear factor κ of activated B cells (NF-κB) [5], pro-
inflammatory cytokines such as tumor necrosis factor
(TNF) and interleukin 1 (IL 1) [6], toll-like receptors 4
(TLR4) [7] , adiponectin [8] and nuclear hormone recep-
tors [9] are related to inflammatory pathways in DN.
Nuclear receptors are found to be the negative regulators
of inflammation, oxidative stress and fibrosis. Vitamin D
receptor (VDR) is one such nuclear receptor involved in
various inflammatory pathways [10].
VDR is a transcription factor and intracellular receptor
for 1-α,25-dihydroxyvitamin D3; an active metabolite of
vitamin D. VDR has been found in proximal and distal
tubular epithelium, glomerular parietal epithelium, collec-
ting duct cells, juxtaglomerular apparatus and podocytes
in kidneys [11]. Experimental studies have shown thatess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
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angiotensin, and angiotensin receptors under diabetic con-
ditions [12] and may develop severe renal injury resulting
in early onset albuminuria, glomerulosclerosis and intersti-
tial fibrosis mainly due to local RAAS activation [13]. Vita-
min D exerts anti-inflammatory effects by modulating
antigen presenting cells function [14], inhibiting dendritic
cell maturation [15], reducing expression of cytokine
interleukin-12 (IL-12), and repressing transcription of
genes encoding interleukin 2 (IL2) and interferon gamma
(INFγ) [16].
Several observational studies have confirmed this patho-
physiologic link between Vitamin D deficiency and DN.
The Third National Health and Nutrition Examination
Survey (NHANES III) found an increase in the prevalence
of albuminuria with decreasing 25(OH)D concentration
[17]. Further evaluation in diabetic population of the sur-
vey showed independent association between Vitamin D
deficiency and diabetic Nephropathy [18]. AusDiab, an-
other large cohort study showed significant association be-
tween 25(OH)D deficiency and impaired eGFR [19]. A
significant relationship between Vitamin D deficiency and
nephropathy may exist, suggesting a possible role of Vita-
min D in delaying the CKD progression.
Vitamin D and its analogues have been used in patients
with CKD with considerable improvement in kidney func-
tions, in terms of reduced urinary albumin creatinine ratio
(UACR) and improved eGFR [20]. However studies evalu-
ating the role of vitamin D in DN are few. There is a need
to critically evaluate the available data and establish any
beneficial association of the use of vitamin D or its ana-
logues in DN. The aim of this review was thus to evaluate
the efficacy of vitamin D and its analogues in the manage-
ment of nephropathy in type 2 diabetic patients and to
summarize the available evidence.
Methods
Studies
We conducted a search for all published, unpublished, on-
going observational or experimental studies, which evaluated
the role of vitamin D or its analogues in the management of
type 2 DN. All studies of type 2 diabetic patients with
nephropathy that reported at least one of the following out-
come measures; Urinary Albumin Creatinine Ratio (UACR),
Urinary Protein Creatinine Ratio (UPCR), Estimated Glom-
erular filtration Rate (eGFR) or albumin excretion rate were
considered for inclusion. Studies with patients with diabetes
other than Type 2, pregnant females, or patients with under-
lying debilitating conditions were excluded.
Search methods
Electronic searches: Electronic databases [MEDLINE,
EMBASE & the Cochrane Central Register of Controlled
Trials (CENTRAL)] and other relevant web sites werecomprehensively searched up to October 2014. The
search was limited to human studies but not to language
or area. The Medical Subject Headings (Mesh) keywords
used to search databases included: “diabetes”, “nephrop-
athy”, and “vitamin D”. Boolean operators were used to
combine all searches (Additional file 1).
Other resources: Search was further supplemented by
reviewing bibliographies of potentially relevant studies.
Authors were contacted for any missing data from the
studies included, or for potentially inclusive studies.
Google Scholar search engine and database (Zetoc) were
also searched for any relevant literature.
Titles, keywords and abstracts of all the relevant studies
were examined by two authors (MKC and MIM) and arti-
cles potentially eligible for full text assessment were identi-
fied. Disagreements were resolved through discussion and
consultation with a third reviewer (ASI).
Selection of studies
Predetermined inclusion and exclusion criteria were
used for all studies. Full text of all potentially relevant
reports were obtained and reviewed by two authors
(MKC and MIM). Study design, types of intervention
(vitamin D and its analogue) and the different outcome
measures (UACR, UPCR, eGFR) were among the inclu-
sion criteria used in this review.
Data extraction and Quality (risk of bias) assessment
For data extraction and to evaluate studies on quality, as-
sessment sheets were specifically prepared for this review
based on the Cochrane Handbook for Systematic Reviews
of Interventions [21] and the Consolidated Standards of
Reporting Trials (CONSORT) [22]. Assessment sheets
addressed randomized and non-randomized studies. Two
reviewers (MKC & ASI) made assessments of sequence
generation, concealment allocation, blinding, incomplete
reporting of outcome measurement data, while determin-
ing the internal validity of included studies. Two reviewers
independently carried out data extraction (MKC & ASI).
The means (or % change in the mean) and standard de-
viation (SD) of all included studies were extracted for
all reported outcome measures. Characteristics of studies
that were analyzed during data extraction were as follows:
type of research design, study methods used, characteris-
tics of participants included, details of outcome measure
and type of analysis used.
Data synthesis
Studies included in the review are presented according to
the study design and then stratified according to the out-
comes reported (UACR, UPCR, eGFR, albumin excretion
rate). Additional outcomes evaluated include; serum 25
(OH) Vitamin D, serum calcium and glycosylated
hemoglobin (HbA1C). Review Manager software (RevMan
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Denmark) was used for data analysis and preparing the re-
view. Effect measures in this review were reported as Mean
Difference (MD) or the percent change (%) in the mean dif-
ferences, their 95 % confidence interval (CI) or their stand-
ard deviations SD [MD (CI/SD)]. The MD and SD were
used for the visual representation of results in the forest
plots. Data of the studies included was stratified based on
the outcome measures reported and was to be pooled de-




The search yielded a total of 572 papers (Medline-502,
Embase-46, CENTRAL-19, others-5). After duplicates
were removed and reports examined by title, keywords and
abstract, they were screened for inclusion and exclusion.
Twenty three papers were considered potentially eligible
for inclusion and were retrieved for evaluation. Of these 23
papers, 17 were excluded after the evaluation (Fig. 1).Fig. 1 Study flow diagramCharacteristics of studies
Included studies
Six studies were short listed for final analysis (Table 1).
Three studies evaluated the effect of cholecalciferol (one
randomized controlled trial (RCT) [23], one non-RCT
[24] and one uncontrolled trial [25]), two of calcitriol
(one RCT [26] and one uncontrolled trial [27]) and one
RCT of paricalcitol [28] in patients with DN. The pa-
tients included in the studies were Vitamin D deficient
with mild to moderate kidney dysfunction. Primary out-
come measures were as follows: percent change UACR
[28], change from baseline in UACR [23–25], change
from baseline in UPCR [26] and albumin excretion rate
(AER) [27]. Other efficacy measures evaluated in the
studies included: eGFR [26, 28], blood pressure [23, 28]
and Transforming Growth Factor-β (TGF-β) [25].
Excluded studies
There were 17 studies excluded from this review. Fifteen
of these excluded studies evaluated overall CKD patients
but did not report any separate data for diabetic pa-
tients, while nine did not evaluate kidney functions as an
Table 1 Characteristics of included studies
Study ID (ref) Design Duration Patients (n) Baseline kidney function Intervention Outcome measures
Cholecalciferol
Kim 2011 [25] Uncontrolled, before-
and-after study
4 months 63 (86 %) patients had eGFR < 60 Vitamin D deficiency: Cholecalciferol 40,000
units weekly for 8 weeks, and then same dose
monthly, and Vitamin D insufficiency:
Cholecalciferol 40,000 units monthly.
UACR, Transforming
Growth Factor-β (TGF-β)
Huang 2012 [24] Controlled, before-and-
after study
6 months 46 (22 Vit D
and 24
placebo)
UACR Mean (CI): Treated grp 97.4
(62.43,476.70) Untreated grp 114.4
(65.15,324.57)
Cholecalciferol daily at a dose of 800 IU/d
over a 6-month period.
UACR
Nooshin 2013 [23] Randomized double
blind placebo controlled
clinical trial
12 weeks 60 (30/30) UACR mean (SD) 120.59 ± 145.40
95.49 ± 57.4
Oral vitamin D3 (pearl 50,000 IU) one pearl
every week for 12 weeks
UACR
Calcitriol
Bonakdaran 2012 [27] Uncontrolled before-
and-after study
8 weeks 43 Albumin excretion rate 0.5 μg calcitriol daily Albumin excretion rate
Mean (SD): 89.9 ± 192.4 GFR mean
(SD): 107.2 ± 22.5
Krairittichai 2012 [26] Randomized clinical trial
(open label)
16 weeks 91(46 vit D/45
placebo)




Zeeuw 2010 [28] Randomized clinical trial
(placebo-controlled,
double-blind)
24 weeks 281 Microalbuminuria (28 %),
macroalbuminuria (72 %)
1 μg paricalcitol (n = 93), or 2 μg paricalcitol
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vitamin D analogues with calcium on kidney functions
and one RCT analyzing the effects of calcitriol on RAAS
activation in type 2 DN patients is ongoing with no pub-
lished results (Additional file 2).
Quality assessment of included studies
Included studies showed high variations in overall
quality. The randomized studies included in this review
varied in their study design, structure and methodology.
Overall risk of bias was low in two RCTs, however the
risk of attrition bias was high as the studies failed to re-
port patients follow up data [23, 28]. There was a high
chance of performance bias in one RCT that did
not report the method for randomization (sequence
generation and allocation concealment) and blinding
[26] (Table 2).
Non-randomized controlled trials had a weaker exter-
nal validity as they lacked full reporting on sample size
calculation and representativeness. Risk of performance
bias was also high for the non-randomized studies. None
of the studies reported blinding of the participant to the
treatment [24, 25, 27]. There was a fair risk of detection
bias in all the three non-randomized studies. Although
the outcome measures were valid and reliable, none of
these non-randomized studies reported blinding of the
assessors to the outcomes. Risk of attrition and selection
bias was high in one particular study with unequal follow
up of the patient groups with no description of patients
lost to follow up and participants in the final analysis
being less than 80 % of the original [27]. None of these
non-randomized studies identified any confounding
factors or reported any adjustments in their statistical
analysis [24, 25, 27] (Table 3).
Effect on renal function
UACR/UPCR/Albumin excretion rate The RCT with
cholecalciferol did not show any significant change in
the UACR (p = 0.84). The treatment group had UACR
(mean ± SD) of 120.59 ± 145.4 mg/g at baseline and
111.49 ± 128.99 mg/g at the end of treatment. The control
group at baseline has UACR (mean ± SD) of 95.49 ±
57.4 mg/g while at end of treatment it was 88.43 ±
65.96 mg/g [23]. The uncontrolled study reported a
significant change in UACR (mean; 95 % CI) with chole-
calciferol from 12.7 (7.3–22.3) mg/mmol to 9.9 (5.5–17.9)
mg/mmol (p = 0.0141) at 2 months. However, this change
was not statistically significant at the end of 4 months
[25]. The non-randomized study showed similar results
as UACR (mean; 95 % CI) decreased significantly from
97.39 (62.43–476.70) mg/g to 71.65 (40.40–469.98) mg/g
(p = 0.01) at 2 months, but again this change was not
significant at 6 months [24].The RCT with calcitriol reported a significant difference
in percent change in UPCR; −18.7 % in calcitriol group
and +9.9 % in control group (p = 0.004) [26]. However, the
uncontrolled study reported beneficial but non-significant
change in albumin excretion rate with calcitriol treatment
[27]. The RCT with paricalcitol showed a between-group
difference versus placebo in the change in UACR of −18 %
(95 %CI −32 to 0), (p = 0 · 053)]. The mean 24 h rate of
albumin excretion also showed significant between-group
difference of −28 % (95 %CI −43 to −8), (p = 0 · 009) [28].
Studies with available data on UACR were pooled together
for a visual representation of the results (Fig. 2). Crude
data was not available for one study for the forest plot
[24]. There was very low heterogeneity between the studies
(I2 = 0 %). Although the test for heterogeneity was not
significant (Chi2 = 0.67, df = 1 [p = 0.41]), meta-analysis
was considered inappropriate because of the small
number of studies and use of different interventions
(cholecalciferol and paricalcitol) [21].eGFR Randomized trials with cholecalciferol [23], calci-
triol [26] and paricalcitol [28] evaluated their effects on
eGFR. Non-randomized trial of cholecalciferol [24] and
uncontrolled studies of cholecalciferol [25] and calcitriol
[27] did not report any crude data. None of these studies
showed any significant benefit in terms of improvement
in eGFR. Available data on studies reporting eGFR were
also pooled for a forest plot (two did not report crude
data [26, 28] (Fig. 3)). The test for heterogeneity was not
significant (Chi2 = 0.67, df = 1 [p = 0.41]). There was no
heterogeneity between the studies (I2 = 0 %). Even then,
meta-analysis was still considered inappropriate with the
small number of studies and use of different interven-
tions (cholecalciferol, calcitriol and paricalcitol) [21].Effect on Serum 25 (OH) Vitamin D
The RCT with cholecalciferol showed a significant
change from baseline in serum 25(OH)Vitamin D levels
(mean ± SD) from 14.06 ± 7.76 to 71.23 ± 26.51 (p= 0.001)
in the treatment group compared to 16.05 ± 6.08 to 17.63 ±
18.52 (p= 0.10) in the control group. The between-group
difference in absolute percentage change was statistically
significant (p < 0.0001) [23]. The non-randomized study also
reported a significant change from baseline in serum
25(OH) Vitamin D levels at 6 months of treatment with
cholecalciferol [17.56 (95 % CI 12.23, 23.83) ng/ml vs. 10.52
(95 % CI 7.75, 11.42) ng/ml]; p= 0.002 [24]. Likewise, a sig-
nificant change in serum 25(OH) vitamin D levels (mean ±
SD) from 15.6 ± 7 to 39.7 ± 12.8; p < 0.0001 was also seen at
4 months of treatment with cholecalciferol in the uncon-
trolled study [25]. Studies of vitamin D analogues (calcitriol
and paricalcitol) did not report after treatment 25(OH) vita-
min D levels.

























✔ ✔ - - - ✔ - ✔ ✔ ✔ ✔
Nooshin
2013 [23]
✔ ✔ ✔ - ✔ ✔ ✔ - - ✔ ✔
Zeeuw
2010 [28]
✔ ✔ ✔ ✔ ✔ ✔ ✔ - - ✔ ✔
Notes: A (✔) indicates the measure was adequately addressed in the study. The absence of a (✔) reflects that either the factor was not measured, or not reported, or did not meet the (✔) requirement; a-studies
received a (✔) if the sample was a random sample of included all eligible diabetic nephropathy with hypovitaminosis D patients from a defined area, or the sample size calculation was justified; b-studies received a

















Table 3 Quality Assessment of Included Studies – Non-Randomized Studies (NRS)
External validity Internal validity
























Kim 2011 [25] ✔ ✔




Notes: A (✔) indicates the measure was adequately addressed in the study. The absence of a (✔) reflects that either the factor was not measured, or not reported, or did
not meet the (✔) requirement; a-studies received a (✔) if the sample was a random sample of included all eligible diabetic nephropathy with hypovitaminosis D
patients from a defined area, or the sample size calculation was justified; b-studies received a (✔) if the % of participation was ≥80; d-studies received a (✔) if
groups were followed within 10 % of each other or for the same time; d-studies received a (✔) if a full description of those lost-to-follow-up was not biased,
or % of participants in the final analysis were ≥80; e-a (✔) indicates that there was adjustments done for confounders in the design or analysis
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The RCT of cholecalciferol reflected significant in-
creases in levels of serum calcium (mean ± SD) from
9.22 ± 0.4 mg/dl to 9.75 ± 0.32 mg/dl (p < 0.0001) in the
treatment group and from 9.40 ± 0.34 mg/dl to 9.76 ±
0.42 mg/dl (p < 0.002) in the control group. There was,
however, no significant difference between the two
groups (p = 0.14) [23]. The non-randomized trial of
cholecalciferol showed no significant changes in the
calcium levels within and between the two groups [24].
There were non-significant changes reported in the rest
of the studies [25–28].
Effect on HbA1c
The RCT evaluating the role of cholecalciferol reported
a non-significant percentage change in HbA1c in both
treatment and control group [23]. The non-randomized
study [24] and the uncontrolled study [25] evaluating
the effect of cholecalciferol on HbA1c also reported
non-significant results. The RCT with calcitriol reported
no significant change in HbA1c levels [26]. Interestingly,
calcitriol effect on HbA1c was found to be statistically
significant in the uncontrolled study where the percent-
age of HbA1c (mean ± SD) changed from 8.4 ± 1.8 to
7.6 ± 1.6 (p = 0.01) in the treatment group [27]. The pari-
calcitol study [28] did not report data on HbA1c.
Discussion
Role of vitamin D and its analogues in the management
of chronic kidney disease (CKD) has been addressed inFig. 2 Forest Plot - Vit D & analogs in Kidney functions in DN - UACRmeta-analyses that reports improvements in the bio-
chemical parameters as well as reduced proteinuria
without any significant adverse effects [20, 29]. The Na-
tional Kidney Foundation-Kidney Disease Outcomes
Quality Initiative (NKF-KDOQI) and Kidney Disease Im-
proving Global Outcomes (KDIGO) clinical practice
guidelines recommends Vitamin D supplementation in
CKD patients with secondary hyperparathyroidism and
associated mineral and bone disorders [30, 31]. However,
literature on Vitamin D effect in the management of DN
is limited. This systematic review summarizes the avail-
able evidence of use of vitamin D or its analogues in
treatment of type 2 DN. We found six studies but with
large variations in designs (three randomized controlled,
one non-randomized controlled and two uncontrolled
studies). Quality assessment revealed low risk of bias in
two of the RCTs included in this review, while it was
unclear-to-high in other studies. Pooling the data for
meta-analysis, stratified according to the assigned inter-
vention and based on the outcomes, was considered in-
appropriate due to differences in study designs and use of
different interventions (cholecalciferol in three studies,
calcitriol in two and paricalcitol in one study).
To our knowledge, this is the first systematic analysis
of data available from studies evaluating the role of vita-
min D or its analogues in the management of DN. The
review showed that treatment with cholecalciferol can
decrease UACR by 7.0 to 26.4 %. However, the studies
included in the review found that the significant reduc-
tion in UACR seen during the initial two months of
Fig. 3 Forest Plot - Vit D & analogs in Kidney functions in DN - eGFR
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[24, 25]. Proteinuria was also reduced significantly with
the use of vitamin D analogues (paricalcitol and calci-
triol) [26, 28]. However the change in proteinuria did
not correspond to the change in eGFR. Vitamin D or its
analogues did not show any deteriorating effects on kid-
ney function. Similar observations were made by reviews
and meta-analysis evaluating the effects of vitamin D
supplementation in patients with CKD [20, 29].
Patients with DN in these studies had vitamin D defi-
ciency, a common manifestation in patients with CKD
[32, 33]. Clinical guidelines recommend a cholecalciferol
dose of 1,000-2,000 IU/d for treatment of vitamin D de-
ficiency in general population and a more aggressive
dosing regimen in patients with CKD [34]. The chances
of hypercalcemia with such doses are rare [35]. Findings
from this review suggest that cholecalciferol supplemen-
tation can result in a significant dose-dependent eleva-
tion in the serum concentrations of 25(OH) D. The
resulting increase in serum calcium concentration was
however not significantly different from that in the pla-
cebo groups suggesting safety of high doses of cholecal-
ciferol in DN patients. Studies evaluating the effect of
vitamin D analogues in this review did not report the
after treatment levels of 25-(OH) vitamin D or 1, 25-
(OH) vitamin D and they did not report any significant
increase in serum calcium concentration.
Another secondary efficacy end point evaluated in this
review was HbA1c. Observational studies have estab-
lished a causal relationship between vitamin D deficiency
and diabetes [36]. Findings in this review suggest that
cholecalciferol and paricalcitol do not affect HbA1c but
calcitriol may reduce it. One meta-analysis reported a
small beneficial improvement in fasting blood glucose
and insulin resistance in patients with abnormal glucose
tolerance receiving vitamin D but no change in HbA1c
was reported. In patients with normal fasting glucose
levels no improvement was seen in any outcome measures
[37]. Another recent review also reported no significant
improvement in glycemic parameters with vitamin D sup-
plementation in patients with diabetes [38].
The role of various proinflammatory molecules have
been identified in the pathogenesis of diabetic nephropa-
thy [39]. Vitamin D exhibits anti-inflammatory properties
by modulating such proinflammatory molecules [14–16].Clinical data also suggest a possible anti-inflammatory role
of calcitriol in DN. Low serum 25(OH) D3 levels were
found to be associated with increased serum and urinary
markers of inflammation such as TNF-α, IL-6, and
ICAM-1 which decreased significantly after calcitriol
treatment [40]. One of the studies included in this review
evaluated the effect of cholecalciferol supplementation on
inflammatory markers such as urinary monocyte chemo-
attractant protein-1 (MCP-1) and transforming growth
factor-β1 (TGF- β1). This study reported a significant de-
crease in urinary TGF- β1 suggesting a potential beneficial
effect of vitamin D [25].
The potential role of vitamin D deficiency in cardio-
vascular morbidity and mortality has been summarized
earlier [41, 42]. Hypovitaminosis D is associated with
asymptomatic cardiovascular disease (CVD) in type 2
diabetic patients with nephropathy [43]. Moreover, vita-
min D deficiency was also found to be prevalent in
hemodialysis patients and is associated with higher all-
cause early mortality [44]. The evidence supporting the
role of vitamin D supplementation in such conditions is
lacking. One study with Alphacalcidiol showed survival
advantage in chronic HD patients [45]. However, a re-
cent meta-analysis concludes that the clinical evidence
on effect of vitamin D supplementation on cardiovascular
mortality is insufficient [46]. None of the studies included
in this review addressed the risk of CVD or survival in
type 2 DN patients.
Studies included in this review were grouped accord-
ing to the study design and sub grouped according to
the different outcomes. With variations in the study de-
sign, interventions and outcomes; pooling of the results
for meta-analysis was considered inappropriate. Method-
ology, conduct and reporting of this review were based
on the recommended guidelines [21]. There is a general
criticism about a one-size-fit-all approach with systematic
reviews. This review however uses an adapted risk of bias
and quality assessment tool. Even though, certain limita-
tions of this review have to be acknowledged. The search
strategy was comprehensive, but there are still chances of
studies being missed. Authors were contacted, but were
unable to provide us with the unpublished or missing data.
Although all reviewers contributed to assessment of qual-
ity of the studies included, there is still a fair likelihood of
personal bias in the review.
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The six studies included in this review evaluating the
role of vitamin D or its analogues in type 2 diabetic ne-
phropathy have large variations in their study designs.
Vitamin D analogues showed significant beneficial ef-
fects on kidney functions. Results also indicated benefits
with high dose cholecalciferol early in the treatment
however the changes were not sustained. Results of
these short duration studies may be ambiguous and
should be read with caution. Vitamin D or its analogues
do not have any negative influence on kidney functions
but monitoring serum calcium levels is important to as-
certain the safety in patients with DN. Experimental
before-and-after studies and studies without control or
comparison groups may not be a suitable study design
for evaluating the effects of vitamin D. Studies with stan-
dardized dose and duration of treatment of vitamin D or
its analogue would provide a clearer picture on the ef-
fects of this supplementation in DN. Randomized
double-blinded controlled trials are needed to further re-
fine these findings and strengthen the current evidence
on the effects of Vitamin D and its analogues on diabetic
nephropathy.
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